Concepedia

Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®)

Marye J. Boers‐Sonderen, Carla M.L. van Herpen, Winette T.A. van der Graaf, Ingrid M.E. Desar, Mirjam G. W. Arens- van der Logt, Yvo M. de Beer, Petronella B. Ottevanger, Nielka P. van Erp

Cancer Chemotherapy and Pharmacology · 2014 · 20 citations · 24 references

DOI

Concepts

References

24

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

E. Eisenhauer, P. Therasse, Jan Bogaerts et al. · European Journal of Cancer · 2008 · 29.5K citations

, , +14

Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes.

Alberto Gabizón, Raphael Catane, Beatrice Uziely et al. · PubMed · 1994 · 1.4K citations

, , +13

Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan

Alan N. Gordon, John Fleagle, David Guthrie et al. · Journal of Clinical Oncology · 2001 · 1.2K citations

, , +16

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

Beatrice Uziely, Susan Jeffers, Rut Isacson et al. · Journal of Clinical Oncology · 1995 · 478 citations

, , +15

Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer

Alan N. Gordon, Margaret Tonda, Steven Sun et al. · Gynecologic Oncology · 2004 · 431 citations

, , +17